18 Aug BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s Pipeline
BioMarin to acquire Alesta Therapeutics for $275M upfront, gaining ALE1 — a potential first oral therapy for hypophosphatasia (HPP)....